Filing Details

Accession Number:
0001753926-24-001576
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-16 16:55:23
Reporting Period:
2024-09-12
Accepted Time:
2024-09-16 16:55:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1919246 Chromocell Therapeutics Corp CHRO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1433316 Ii Knuettel Francis C/O Chromocell Therapeutics Corporation
4400 Route 9 South, Suite 1000
Freehold NJ 07728
Ceo, Pres., Cfo, Treas & Secty No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-12 1,700 $0.97 544,210 No 4 P Indirect By Lara Knuettel Revocable Trust
Common Stock Acquisiton 2024-09-13 3,500 $0.97 547,710 No 4 P Indirect By Lara Knuettel Revocable Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Lara Knuettel Revocable Trust
No 4 P Indirect By Lara Knuettel Revocable Trust
Footnotes
  1. This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This price represents the weighted average price of the shares purchased ranging from $0.93 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
  2. This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This price represents the weighted average price of the shares purchased ranging from $0.94 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.